Product Overview
[Drug name]
Generic name: Ornidazole vaginal suppository
Trade name: YouRu Ornidazole vaginal suppository 0.5g*6 tablets
Pinyin full code: YouRu AoXiaoZuoYinDaoShuan 0.5g*6Li
"Main ingredients"
The main ingredient of this product is ornidazole.
[Properties]
This product is a white or off-white suppository.
[Indications/Main functions]
Bacterial vaginosis, Trichomonas vaginitis.
[Specifications]
0.5g*6 tablets
[Usage and dosage]
Vaginal administration every night before going to bed. Wash the vulva and insert the suppository deep into the vagina with clean hands. Once a night, 1 tablet at a time, for 7 consecutive days.
[Adverse reactions]
Occasionally, vulvar burning pain, vulvar skin itching, vulvar skin papules, vulvar Skin redness, occasional increase in vaginal discharge. Although the amount of this product absorbed by the body is low, there is still a small amount of absorption. Therefore, attention should be paid to the adverse reactions of systemic absorption of this product. The adverse reactions of systemic administration of ornithine include: 1. Digestive system: including mild stomach discomfort, stomach pain, bad breath, etc.; 2. Nervous system: including headache and drowsiness, dizziness, tremors, numbness of limbs, cramps and mental confusion, etc.; 3. Allergic reactions: such as rash, itching, etc.; 4. Local reactions: including tingling, pain, etc.; 5. Others: leukopenia, etc.
Contraindications Taboos
1. It is contraindicated for patients who are allergic to this product and other nitroimidazole drugs; 2. It is contraindicated for patients with brain and spinal cord lesions, epilepsy and various organ sclerosis; 3. It is contraindicated for patients with organ sclerosis, hematopoietic dysfunction, and chronic alcoholism
[Drug Interactions]
1. Compared with other nitroimidazole drugs, this product has no inhibitory effect on acetaldehyde dehydrogenase. 2. Ornidazole can inhibit the metabolism of the anticoagulant warfarin, prolong its half-life, and enhance the efficacy of anticoagulants. When used with warfarin, the prothrombin time should be observed and the dosage should be adjusted. 3. Barbiturates, ranitidine, cimetidine and other drugs can accelerate the elimination of ornidazole and reduce its efficacy and affect coagulation, so they should be contraindicated for combined use. 4. Simultaneous use of phenytoin sodium, phenobarbital and other drugs that induce liver microparticles Drugs that inhibit endogenous enzymes can enhance the metabolism of this product, reduce blood drug concentration, and slow down the excretion of phenytoin sodium. 5. Ornidazole can delay the effect of muscle relaxant vecuronium bromide.
[Precautions]
1. Avoid sexual intercourse during treatment. 2. Do not use the drug during menstruation. 3. If improperly stored, this product softens or melts. It can be placed in a refrigerator or cold water and used after cooling and forming. It does not affect the efficacy. 4. Please keep this product out of reach of children.
[Children's use]
There is no experience in using this product for children.
[Elderly patients' use]
Same as adults.
[Overdose]
Please use strictly according to the doctor's prescribed dosage. Overdose of this drug can aggravate adverse reactions. If serious adverse reactions occur, stop using this drug immediately and seek timely treatment.
[Pharmacology and toxicology]
Physical action: This product is the first The third generation of nitroimidazoles may exert their antimicrobial effects through the mechanism of reduction of the nitro group in its molecule to amino group in an anaerobic environment or through the formation of free radicals that interact with cellular components, thereby causing the death of microorganisms. Toxicological studies: Repeated dose toxicity: Rats were given this product at a dose of 400 mg/Kg/day for 2 consecutive years, and there was no effect on the life span of the animals, nor did it cause serious functional or morphological changes. Dogs were given the drug for 1 year at a dose of 250 mg/kg/day, and central nervous system symptoms appeared. These symptoms can be seen in rat tests of nitroimidazoles. Genotoxicity: Similar to other nitroimidazole drugs, this product is mutagenic to a variety of strains, but dominant lethal tests on human lymphocytes and mice show that this product has no mutagenic effects on a variety of strains. The product has no effect on mammalian cell chromosomes. Reproductive toxicity: In high-dose studies conducted on rats, mice and rabbits, there was no significant effect on the fetus and perinatal period. No teratogenic effect was observed when the dose of rats and mice reached 400 mg/kg/day and the dose of rabbits reached 100 mg/kg/day. Oral administration can inhibit the reproductive ability of male rats, but unlike other 5-nitroimidazole compounds, this product does not inhibit sperm production. However, there is currently no sufficient and strictly controlled clinical research data on pregnant women. Since animal reproduction studies cannot fully predict the effects of drugs on humans, this product can only be used during pregnancy when it is really necessary. Carcinogenicity: Rats were given a dose of 400 mg/kg/day for 2 consecutive years, and no tumorigenicity was observed for this product.
